Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

Solutions Holdings PLC
24 May 2007


Plethora Enters Into Exclusive License Agreement with
Sciele to Market PSD502
for the Treatment of Premature Ejaculation

Sciele Pharma to Purchase $7 Million Equity Stake in Plethora

ATLANTA, LONDON (May 24, 2007) Sciele Pharma, Inc. (NASDAQ:SCRX) and Plethora
Solutions Holdings plc ('Plethora', AIM:PLE) announced today that they have
signed an exclusive license agreement for the marketing of PSD502 for premature
ejaculation (PE) in the United States together with an agreement for Sciele to
purchase a $7 million equity stake in Plethora. Plethora is developing
innovative products for women's health and male sexual dysfunction. Plethora has
products in clinical development for the treatment of premature ejaculation,
overactive bladder, stress urinary incontinence, interstitial cystitis and
gynecological pain.

Under the terms of the license agreement, Plethora will receive payments upon
achievement of regulatory and sales milestones, and royalty payments on product
sales. Plethora will have co-promotion rights for urologists in the United
States.

PE is the most common form of sexual dysfunction among men. PE is estimated to
affect approximately 25% to 30% of men of all ages (Laumann et al1999 JAMA
281537-44). According to the results of this survey, approximately 25 million
men between the ages of 18 and 59 in the U.S. experience PE.

PSD502 comprises a unique, proprietary, and rapidly absorbed formulation of two
well-established local anesthetics, lidocaine and prilocaine, dispensed in a
metered dose spray. Plethora has completed a phase II clinical trial using
PSD502, and Plethora is expected to begin a phase III study in the second half
of 2007.

Under the agreement to purchase a $7 million equity stake in Plethora, Sciele
has purchased 1,772,505 new Ordinary Shares in Plethora at 2.00 per share.

Patrick Fourteau, Chief Executive Officer of Sciele, said, 'We are pleased to
take an equity stake and enter into this collaboration with Plethora as they are
developing new products for Women's Health and sexual dysfunction. This
partnership will enable us to further expand our product pipeline and leverage
our sales force. We are enthusiastic about PSD502, which may provide a potential
PE treatment, addressing an unmet medical need for millions of men.'

Steven Powell, Chief Executive Officer of Plethora, said, 'We are delighted to
have Sciele as a licensing partner and welcome them as a shareholder. We look
forward to working with Sciele and to updating our shareholders on progress with
licensing PSD502 for premature ejaculation elsewhere in territories outside the
USA.'

About Plethora Solutions:

Plethora is focused on the development and marketing of products for the
treatment of urological disorders. The Company has products in clinical
development for the treatment of overactive bladder, stress urinary
incontinence, interstitial cystitis, gynecological pain and premature
ejaculation. In January 2006, Plethora acquired Minneapolis (MN) based Timm
Medical Technologies, Inc. which markets the ErecAid(R) and Rigiscan(R) products
for the treatment of erectile dysfunction (ED) to urology clinics through a
US-based specialty sales team. Most recently, the ErecAid has been found to be
effective for men that fail Medical Management and for men recovering from
prostatectomy The Company is headquartered in the UK and is listed on the London
Stock Exchange (AIM:PLE) Further information is available at

www.plethorasolutions.co.uk


About Sciele Pharma, Inc.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing
and development of branded prescription products focused on Cardiovascular/
Diabetes and Women's Health. The Company's Cardiovascular/Diabetes products
treat patients with high cholesterol, hypertension, high triglycerides, unstable
angina and Type 2 diabetes, and its Women's Health products are designed to
improve the health and well-being of women and mothers and their babies. Founded
in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than
800 people. The Company's success is based on placing the needs of patients
first, improving health and quality of life, and implementing its business
platform - an Entrepreneurial Spirit, Innovation, Speed of Execution,
Simplicity, and Teamwork.

Safe Harbor Statement

This press release contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results to materially differ from
those described. Although we believe that the expectations expressed in these
statements are reasonable, we cannot promise that our expectations will turn out
to be correct. Our actual results could be materially different from and worse
than our expectations. With respect to such forward-looking statements, we seek
the protections afforded by the Private Securities Litigation Reform Act of
1995. These risks include, without limitation

Plethora Solutions Holdings PLC
24 May 2007



PLETHORA SOLUTIONS HOLDINGS PLC

Plethora Solutions Holdings PLC ('Plethora', AIM: PLE), a company specialising
in the development and marketing of products for the treatment and management of
urological disorders, will be announcing its preliminary results for the year
ended 31st December 2006 on Wednesday 30th May 2007.

An analyst meeting will be held at 10am at the offices of Collins Stewart, 9th
Floor, 88 Wood Street, London EC2V 7QR

-Ends-

For further information contact:

Plethora Solutions Tel: 020 7269 8630
Steven Powell

City/Financial Enquiries Tel: 020 7379 5151
Maitland
Brian Hudspith/Liz Morley

Scientific/Trade Press Enquiries Tel: 020 7861 3838
De Facto Communications
Richard Anderson

About Plethora Solutions:

Plethora is focused on the development and marketing of products for the
treatment of urological disorders. The Company has products in clinical
development for the treatment of overactive bladder, stress urinary
incontinence, interstitial cystitis, gynaecological pain and premature
ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm
Medical Technologies Inc which markets the ErecAid(R) and Rigiscan(R) products
for the treatment of erectile dysfunction (ED) to urology clinics through a
US-based specialty sales team. Most recently, the ErecAid has been found to be
effective for men that fail Medical Management and for men recovering from
prostatectomy The Company is headquartered in the UK and is listed on the London
Stock Exchange (AIM:PLE) Further information is available at

www.plethorasolutions.co.uk

Patience always pays off with good stocks!

Hondaman, well done with the posts. I just hope that this will prove to be a good stock, as my patience has been a little bit tried over the past few months!

I wonder how big the PSD502 deal actually is . . . .

However, it's definitely a good sign that Sciele paid 2 a share for its equity stake.

I think another good sign is that PLE is meeting with analysts once its results are published. Clearly the co thinks it can provoke a rerating.

soul traders -don't forget the other PSD502 deals for woundpain and PE for other world areas have yet to come. Next week they will probably give actual figures to the deal. I like the deal because Plethoras other major products fit well into Sciele's organisational portfolio too -The OAB products are even massive.

And they have a good deal with MLR

they have
signed an exclusive license agreement for the marketing of PSD502 for premature
ejaculation (PE) in the United States together with an agreement for Sciele to
purchase a $7 million equity stake in Plethora.

This is interesing because they state that they have signed an exclusive license agreement together with the stake -so that means the agreement terms will be announced I guess next week on 30th May ref royalty payments etc -just my conclusion!!!

I have my doubts as to whether we'll learnt the terms of the deal. Why did PLE not announce them today?

soul -its clear that we haven't had the whole information -reason I guess is that the results are on 30th May so it would make sense to blend everything in together with all other financial info. But the wording in todays news is clear that more info will be given. The clue is the word "together" in the news. Together is the Sciele purchase of shares but the deal agreement info should follow -some peeps haven't cottoned on yet I guess.
It'll get to 2 anyway I guess based on the purchase info.

MM's have woken up -they are buying now -ready for next week and beyond!

Up again today: PLE Bid: 174p Offer: 181p Change: 2.5

Dumped this and bought HAWK. Have spent too long waiting for PLE to do something spectacular on the back of the PE product deal, which it hasn't done. Will watch and see how increased revenues affect this in the future, but am on the sidelines for now.

Good luck to holders.

does anyone understand why PLE has moved to FTSE AIM 50??

watch PLE watch MLR

watch PLE - based on??

The fact that a 100% of males, real males that is, not whimpish poofters, want a hard on and only about 75%(BMJ) are able to.

It's about half the sp when you posted David10B - what can you suggest is the reason? . . . . I agree that this appears to be a product men would give their rt arm for (almost), yet now it's at an all-time low - although not that low I'm tempted to buy for "recovery". This slide looks like carelessness - eyes-off-balls etc.

I note that a PhIII-trial is to start for premature ejaculation - something like the hullabaloo over the SP a few years ago....Maybe it's the "Jam tomorrow" problem over again...

EDIT(17Nov08)-16p/19p . . . As I read it, the erectile product is a vacuum-device, whereas I was believing this company was offering a drug-pased product. Doh! - this was 1 only last November!
- Anyone? -

LONDON (ShareCast) - Plethora Solutions (LSE: PLE.L - news) is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler.

Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two phase III trials and is currently awaiting European approval. This approval is expected late in the third quarter or early fourth quarter of 2013.

Importantly, it announced at its interims on December 28th that talks "had commenced with multiple parties to identify a commercial partner to bring PDS502 product to market.

Alexandre believes the stock is "grossly undervalued" and has placed a price target of 15.7p on it, 214% upside on its current 5p price.

Now, as house broker you might perhaps expect him to be keen on the stock but he's positively enthusiastic, while noting that its closing cash balance at the interims was only £0.2m, which means: "We estimate that the company will need to secure further financing."

He's confident that the next 12 months will see the transformation of the company, with the signing of a deal probably before EU approval, as any partner would have to factor in a ramp-up period prior to the product's launch. With that deal would come some sorely needed funds.

With an estimated 30m European men as potential targets for this treatment it may be a compelling investment case.

Alexandre thinks it is: "We believe that PSD502 has the potential to 'go mass market'. Should this transpire, our estimates of the treatment's market potential would be significantly increased. That said, even if the treatment achieves a fraction of this market penetration, Plethora's business would be substantially transformed."

For those of a cautious disposition, who like to invest in well-funded companies, it might be worth holding off until any deal is announced. Yet, the fact that billionaire Jim Mellon, a non-executive director of the company, has been funding the company in return for shares, ought to offer some reassurance for those prepared to gamble on this biotech play.